FDA Approves SYMBICORT for COPD Exacerbations

Article

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.

The US Food and Drug Administration (FDA) has approved an update to the label of chronic obstructive pulmonary disease (COPD) treatment budesonide/formoterol fumarate dehydrate (SYMBICORT) to indicate its reduction of COPD exacerbations.

SYMBICORT, by pharmaceutical company AstraZeneca, is a pressurized metered dose inhaler (pMDI) 160/4.5 micrograms and fromoterol 4.5 micrograms, administered as 2 inhalations per day for treating exacerbations in moderate-to-severe COPD adult patients.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care. SYMBICORT supplementally treats chronic bronchitis and emphysema, but is not indicated for acute bronchospasm relief.

The most commonly reported adverse effects in COPD clinical trials included bronchitis, sinusitis, upper respiratory tract infection, and other conditions. However, the rate of adverse effects did not exceed 3% of the studied patient population.

Frank Trudo, USMA Respiratory Brand Medical Lead, said the "important indication" allows AstraZeneca to communicate to healthcare providers the impact SYMBICORT has in helping reducing COPD exacerbations, which is "an important outcome to avoid for those who are being treated for COPD."

"This marks the second new indication for SYMBICORT in 2017, which illustrates our commitment to follow the science," Trudo said.

According to AstraZeneca, more than 14 million people in the US were diagnosed with COPD as of 2010, and another 12 million people have not been diagnosed.

Related Coverage

Reconsidering the Role of Inhaled Steroid for Early Childhood Asthma

Dupilumab Treats Asthma Exacerbation, Lung Function in Phase 3 Trial

Comprehensive Asthma Interventions Effective in Real-World Communities

Recent Videos
A panel of 3 experts on COPD
A panel of 3 experts on COPD
A Promising Pipeline for COPD
Projecting Dupilumab's Fit in COPD
What the Ensifentrine FDA Approval Means for COPD
3 KOLs are featured in this program.
3 KOLs are featured in this program.
Video 10 - "Future Treatment Landscape for COPD"
Video 9 - "Emerging Treatment Approaches in COPD"
Pavel Strnad, MD | Credit: RWTH Aachen
© 2024 MJH Life Sciences

All rights reserved.